

**BIOCON GROUP**

**FACT SHEET**

**June - 2014**

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>BALANCE SHEET</b>		<b>(Rs. Crores)</b>	
	<b>June 30, 2014</b>	<b>March 31, 2014</b>	
<b>EQUITY AND LIABILITIES</b>			
<b>Shareholder's Funds</b>			
(a) Share capital	100	100	
(b) Reserves and surplus	3,034	2,927	
	<b>3,134</b>	<b>3,027</b>	
<b>Minority interest</b>			
	87	82	
<b>Non-current liabilities</b>			
(a) Long-term borrowings	704	606	
(b) Deferred tax liability (net)	45	45	
(c) Other long-term liabilities	628	603	
(d) Long-term provisions	8	8	
	<b>1,385</b>	<b>1,262</b>	
<b>Current liabilities</b>			
(a) Short-term borrowings	227	244	
(b) Trade payables	446	347	
(c) Other current liabilities	464	612	
(d) Short-term provisions	189	177	
	<b>1,326</b>	<b>1,380</b>	
<b>TOTAL</b>	<b>5,932</b>	<b>5,751</b>	
<b>ASSETS</b>			
<b>Non-current assets</b>			
(a) Fixed assets	2,818	2,719	
(b) Goodwill	12	12	
(c) Non-current investments	65	65	
(d) Long term loans and advances	268	269	
(e) Other non-current assets	168	47	
	<b>3,331</b>	<b>3,112</b>	
<b>Current assets</b>			
(a) Current Investments	489	700	
(b) Inventories	379	377	
(c) Trade receivables	664	600	
(d) Cash and cash equivalents	855	804	
(e) Short term loans and advances	133	82	
(f) Other current assets	81	76	
	<b>2,601</b>	<b>2,639</b>	
<b>TOTAL</b>	<b>5,932</b>	<b>5,751</b>	

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crores)
Particulars	Q1 FY 15	Q1 FY 14	Variance
<b><u>INCOME</u></b>			
<b>Biopharmaceuticals</b>	<b>547</b>	<b>540</b>	<b>1%</b>
Biopharma *	436	439	-1%
Branded formulations - India	111	101	10%
<b>Contract research</b>	<b>172</b>	<b>154</b>	<b>12%</b>
<b>Total Sales</b>	<b>719</b>	<b>694</b>	<b>3%</b>
Other income	23	29	-19%
<b>Total Revenue</b>	<b>742</b>	<b>723</b>	<b>3%</b>
<b><u>EXPENDITURE</u></b>			
Material & Power costs	334	338	-1%
Staff costs	116	107	8%
Research & Development **	31	43	-28%
Other expenses	70	60	17%
<b>Manufacturing, staff &amp; other expenses</b>	<b>551</b>	<b>548</b>	
<b>EBITDA</b>	<b>191</b>	<b>175</b>	<b>9%</b>
Interest & Finance charges	1	-	
Depreciation & Amortisation	52	49	5%
<b>PBT</b>	<b>138</b>	<b>126</b>	<b>10%</b>
Taxes	31	29	8%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>107</b>	<b>97</b>	<b>11%</b>
Minority interest	4	3	
<b>NET PROFIT FOR THE PERIOD</b>	<b>103</b>	<b>94</b>	<b>9%</b>
<b>EPS Rs.</b>	<b>5.2</b>	<b>4.7</b>	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	19	8	
** Gross Research & Development expenses	38	47	

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			<b>(Rs. Crores)</b>
Particulars	Q1 FY 15	Q4 FY 14	Variance
<b>INCOME</b>			
<b>Biopharmaceuticals</b>	<b>547</b>	<b>535</b>	<b>2%</b>
Biopharma *	436	442	-2%
Branded formulations - India	111	93	19%
<b>Contract research</b>	<b>172</b>	<b>188</b>	<b>-8%</b>
<b>Total Sales</b>	<b>719</b>	<b>723</b>	<b>-1%</b>
Other income	23	23	-
<b>TOTAL REVENUE</b>	<b>742</b>	<b>746</b>	<b>-1%</b>
<b>EXPENDITURE</b>			
Material & Power costs	334	332	1%
Staff costs	116	112	4%
Research & Development **	31	29	7%
Other expenses	70	80	-13%
<b>Manufacturing, staff &amp; other expenses</b>	<b>551</b>	<b>553</b>	
<b>EBITDA</b>	<b>191</b>	<b>193</b>	<b>-1%</b>
Interest & Finance charges	1	1	
Depreciation & Amortisation	52	54	-4%
<b>PBT</b>	<b>138</b>	<b>138</b>	<b>0%</b>
Taxes	31	19	
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>107</b>	<b>119</b>	<b>-10%</b>
Minority interest	4	6	-26%
<b>NET PROFIT FOR THE PERIOD</b>	<b>103</b>	<b>113</b>	<b>-9%</b>
<b>EPS Rs.</b>	<b>5.2</b>	<b>5.7</b>	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	19	-	
** Gross Research & Development expenses	38	38	